Topics
Glioblastoma | Treatment | Targeted therapy | Navtemadlin
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Navtemadlin
Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Reynolds ARN,
Fassinou ACR, Ayoub G, Lapinskas E, Pisano W, Jeang J, Stopka SA,
Regan MS, Spetz J, Desai A, Lieberman F, Fisher JD, Pelton K,
Huang RY, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S,
Walbert T, Ye X, Agar NYR, Grossman SA, Alexander BM, Wen PY,
Ligon KL, Beroukhim R.
Surgical window
of opportunity trial reveals
mechanisms of response and resistance
to navtemadlin (KRT-232) in patients with
recurrent glioblastoma.
medRxiv
[Preprint]. 2024 Aug 14:2024.08.12.24311893. doi:
10.1101/2024.08.12.24311893. PMID:
39211865. Interventional study. ˍ